George
waitin' fer rabbits
- Messages
- 853
- Location
- South Texas
I need to clean this up but it was kinda stream of con, con, well, brain cells
They all want to leave? (grins)
gilliad science - xmrv are their 4 and what do we call them
are we dealing with 1 or more pathogenic agents- stoye
coffin - xmrv is a replicating virus the other sequence are still unknown not complete sequences insertion sequence that could render other sequence inert.
ruscetti- want's to check transmissible of poly's, recombinate???
judy- we have 500 isolate to check then sequence the entire mess.
gallen marshal Univ miss. - methodogy being vehimetly discussed. when can we get a unified method of detection? is that on the horizon
judy - nice assay from rachale and we are going to do this in the blood working group we are closer
jerry holmberg- the blood working group through this group we will come up with a standard test. and sample prep for a more stardart
coffin - it's only been a year, 6 months to just get it all together the blood working group. diffrent assays for xmrv like HIV- zone of chaos. no agreement on anything. but we'll get there soon
john mellers Uni pittsburg - CFS struck by highly divergent from 0 to 80 percent, could be diffrent patients or diffrent metholgy. just get a group of patients and test via diffrent labs. everybody test the same samples for all the diffrent methodologies. to resolve from 0 to 80 it's got to be the same samples.
jerry h - goal of the bwg, the panel should be able to get a set of patients, we've been using only judy's patients. we need a geo distribution. lack of standard. we want to get a panel established.
judy - heard from cheny, kamoroff, bell, and ???? thiese are good set of patients from all over the world we can begin to address the patients because the doctors have the positive patients.
in singh - xmrv ready for prime time, want to echo importance that we need to cross validate these assays, HPV research progress was achieved when a standard test. cant establish causality untill a stardard test. must have a coordinatied effor amoung the labs must be to move forward. collaborate, collaborate, collaborate.
stoy - the immuniolgist complaining about the virologiist, it will happen quickly.
???? - distract me from kosacs talk an iron curtain through europe that mice virus the derus assay may not have the sequenc biasis
stoy - you have to deveolope an antibody or PCR in order to screen large numbers then we can get on to other things
???? - fukda criteria?? are doctors the doctors
judy - critera is variable in doctors. we use tests to define the patient population
clinical chohorts need
judy - need bio markers
job clinicinal - groups find find 2/3 or 0 it is very important, collection and storage before running
judy - true we have learned in the last two weeks that processing may be the key we may be albe to find viral rna in plam
minda cfscental - when are we going start treatment
john - premature until the pathophisology of the illness, HIV is blocked costant replication of virus. I surprised about hiv behaves diffrent, it's only because of the no antiviral works without constant replication, PC not the case of replication, once the cancer arises is not in the case of CFS but it might have ongoing on replication, arguments that going into the trialscould work, judy says yesssss
but we don't know what's going on, till we have
mindy -how long will that take???
coffoin- counter productive to do ARV right now.
Hilliary - Judy your opion
judy cant' answer that
dodd from red cross - I've heard a lot of incompatable information, high level hypothosis, we're not doing this or that or that but I would like fro the plausalbe mech from the virologisty what's we are speculate
stoy technical details first then we can give you a hypothosis, the more interesting ideals, don??
don - I would say from carconagens not everyone gets cancer, genetics of the host may play a role as well with CFS but we don't know enought to handle questions.
frank???? - funding is there any plans to get the NCI funding
???interest in the NIH and NCI and FC was here and listening and looking at funding options and how do we go about stimulating the funding in the area. R1 aplication are small. and we need good ideals for the funding to be granted, as thing s devolope then we can suspect the NCI and NIH will be able to provide funding.
frank - man from pitts burge, need multi disipinariany grants
???PO 1 project and focused and some of the project and get the information through. encourage them to appy
coffin - turned away from the confrence, and this money funds diverted from preivious projects into this area. that we can do this with discretionay fund but we need long term moneys and sustain the momentum zone of chaos but all fields go through the sausage making but it's going pretty good
????angleo ptholgisy from joh hopkins - negative studys are scaring people off from negative studies, that it wouldn't be that hard to find there was 17 confermitory paper but everybody got to find it and why do we have so many negative studies, the studys were good why the problems
judy - pcr, and that's not how we find retroviruss not virus, and the problems with finding in the cells and hiv and htlv used a varity of methods and to may are using
myra mclure - seology but it's just not thei
judy - 50 posistive from london
myra - indepently sent
judy - validated
myra - well, fine now but I don't want to see independen
judy wow o.k.
reasonable from cdc and fda and validated test we don't know what the diffrences but I recomment that negative pcr for detection of this virus in clinical samlpe
myra -
steve climin aabb - general accepting results, in PC and CFS mutations in rna's but now it's not true what is the prediletion? to tie together my question is can you figure why diffrents, immunosuppression or passager virus
judy - RO 1 studieys about theinate immune responsce?
stoy - there is a defect or immunse suppresion but we don't know
coffin - makes visiable a virus could the disease make the virus
???? shif gears, seperate cfs and pc the epidemiolgy may be diffrent and look at the thearpys in the public domain is friegtening leads to the imagination of scary, what's happening a comppletly micro epidimic because of treatments/??? that doest have a nothing to do with cfs and PC or the pathogeniss
styo is anyone say the epdim is the same??
??? that the two is incompatiable with the same pathogents
david GSC - mulitpul virus sample of cfs or pcr or serology is evey
judy to llok at all the virus, cfs have a lot of active virus, lyme, micro plasim, the rv creates aides to not be able to controll as in the HIV early days 25 aids defining illnesses. and are look at all of those the
david - but is xmrv just a pass
judy - in geernaly rv don't just hang out but we expect to see that it will cause problems
???? negative studys we still don't know reported on the disease since 1984 they have depression the emperic definition have 38% depression we don't know but let's define the patient, but we have people who have been sick for 40 or more years, RKI didn't switzer and trade sample s with a lab that
stoy - enogh nobodys trying to get a negivtive results.
hj -
stoy -
coffin - we got to get this sort this out before we start druggs but we are not their mean time lay off the drugs
??? don't offten find rv most gibbons don't get ill
sniderman ny- passager virus?? since you can't give the kocks postulate how can the find pathogensis
john - hiv giving the arv showing the disease was an argument for showing causality but we had a lot more science under us befoer that happened and we don't have the at yet. Nowif we could quaintative assays then maybe yeat then maybe we could
???? hiv and hemophiliacs so you were closer
coffin - but until we get the right assessys
bell- progress hive thour the mistakes we lost people who were not able to side effect to tret people with the drugs to keep from making the same mistakes
???- we learned a lot from HIV epidemic and the hemophilia took the brunt of it, dr. bell? but I have to say that that NHIBL repository's helped to make linked to donor and recipiant and tap and try to identify xmrv epidemiology
??? don't take a heterogenoud groups gets assembling a group of patiens with cfs and well as controls and dfine and standard collection and establish and if you can quanitiy it then you could do a clinic trial but we have to define the patients. we need a step wise approach and do phase 1 and 2 and then longer term for clinica benifit
judy - hundreds xmrv positie people who are very sick and the commentary in those patient population and have not had a life for 25 years and more than the
???? i think you are on the right track but independy validated, and not the underliying sceptiums of people who are bed bound, and extended to diffrent groups
judy - independent groups validated and the patient exits, three positive and posters and followed using dersu assays. there are signiicant numbers with the virus from diffrent gourps
coffin - quaintative virus assay in a patient cohort and then maybe do a study to look at the arv could happen soon but the assasys that we have now but we need a quaintave assay that gives u a reproducable result. Then we could do something like tat with cross overs and monitor clinicly.
stoy - other issues
nation c inst - HPV animal model then you can make it certain, induce illness,
They all want to leave? (grins)
gilliad science - xmrv are their 4 and what do we call them
are we dealing with 1 or more pathogenic agents- stoye
coffin - xmrv is a replicating virus the other sequence are still unknown not complete sequences insertion sequence that could render other sequence inert.
ruscetti- want's to check transmissible of poly's, recombinate???
judy- we have 500 isolate to check then sequence the entire mess.
gallen marshal Univ miss. - methodogy being vehimetly discussed. when can we get a unified method of detection? is that on the horizon
judy - nice assay from rachale and we are going to do this in the blood working group we are closer
jerry holmberg- the blood working group through this group we will come up with a standard test. and sample prep for a more stardart
coffin - it's only been a year, 6 months to just get it all together the blood working group. diffrent assays for xmrv like HIV- zone of chaos. no agreement on anything. but we'll get there soon
john mellers Uni pittsburg - CFS struck by highly divergent from 0 to 80 percent, could be diffrent patients or diffrent metholgy. just get a group of patients and test via diffrent labs. everybody test the same samples for all the diffrent methodologies. to resolve from 0 to 80 it's got to be the same samples.
jerry h - goal of the bwg, the panel should be able to get a set of patients, we've been using only judy's patients. we need a geo distribution. lack of standard. we want to get a panel established.
judy - heard from cheny, kamoroff, bell, and ???? thiese are good set of patients from all over the world we can begin to address the patients because the doctors have the positive patients.
in singh - xmrv ready for prime time, want to echo importance that we need to cross validate these assays, HPV research progress was achieved when a standard test. cant establish causality untill a stardard test. must have a coordinatied effor amoung the labs must be to move forward. collaborate, collaborate, collaborate.
stoy - the immuniolgist complaining about the virologiist, it will happen quickly.
???? - distract me from kosacs talk an iron curtain through europe that mice virus the derus assay may not have the sequenc biasis
stoy - you have to deveolope an antibody or PCR in order to screen large numbers then we can get on to other things
???? - fukda criteria?? are doctors the doctors
judy - critera is variable in doctors. we use tests to define the patient population
clinical chohorts need
judy - need bio markers
job clinicinal - groups find find 2/3 or 0 it is very important, collection and storage before running
judy - true we have learned in the last two weeks that processing may be the key we may be albe to find viral rna in plam
minda cfscental - when are we going start treatment
john - premature until the pathophisology of the illness, HIV is blocked costant replication of virus. I surprised about hiv behaves diffrent, it's only because of the no antiviral works without constant replication, PC not the case of replication, once the cancer arises is not in the case of CFS but it might have ongoing on replication, arguments that going into the trialscould work, judy says yesssss
but we don't know what's going on, till we have
mindy -how long will that take???
coffoin- counter productive to do ARV right now.
Hilliary - Judy your opion
judy cant' answer that
dodd from red cross - I've heard a lot of incompatable information, high level hypothosis, we're not doing this or that or that but I would like fro the plausalbe mech from the virologisty what's we are speculate
stoy technical details first then we can give you a hypothosis, the more interesting ideals, don??
don - I would say from carconagens not everyone gets cancer, genetics of the host may play a role as well with CFS but we don't know enought to handle questions.
frank???? - funding is there any plans to get the NCI funding
???interest in the NIH and NCI and FC was here and listening and looking at funding options and how do we go about stimulating the funding in the area. R1 aplication are small. and we need good ideals for the funding to be granted, as thing s devolope then we can suspect the NCI and NIH will be able to provide funding.
frank - man from pitts burge, need multi disipinariany grants
???PO 1 project and focused and some of the project and get the information through. encourage them to appy
coffin - turned away from the confrence, and this money funds diverted from preivious projects into this area. that we can do this with discretionay fund but we need long term moneys and sustain the momentum zone of chaos but all fields go through the sausage making but it's going pretty good
????angleo ptholgisy from joh hopkins - negative studys are scaring people off from negative studies, that it wouldn't be that hard to find there was 17 confermitory paper but everybody got to find it and why do we have so many negative studies, the studys were good why the problems
judy - pcr, and that's not how we find retroviruss not virus, and the problems with finding in the cells and hiv and htlv used a varity of methods and to may are using
myra mclure - seology but it's just not thei
judy - 50 posistive from london
myra - indepently sent
judy - validated
myra - well, fine now but I don't want to see independen
judy wow o.k.
reasonable from cdc and fda and validated test we don't know what the diffrences but I recomment that negative pcr for detection of this virus in clinical samlpe
myra -
steve climin aabb - general accepting results, in PC and CFS mutations in rna's but now it's not true what is the prediletion? to tie together my question is can you figure why diffrents, immunosuppression or passager virus
judy - RO 1 studieys about theinate immune responsce?
stoy - there is a defect or immunse suppresion but we don't know
coffin - makes visiable a virus could the disease make the virus
???? shif gears, seperate cfs and pc the epidemiolgy may be diffrent and look at the thearpys in the public domain is friegtening leads to the imagination of scary, what's happening a comppletly micro epidimic because of treatments/??? that doest have a nothing to do with cfs and PC or the pathogeniss
styo is anyone say the epdim is the same??
??? that the two is incompatiable with the same pathogents
david GSC - mulitpul virus sample of cfs or pcr or serology is evey
judy to llok at all the virus, cfs have a lot of active virus, lyme, micro plasim, the rv creates aides to not be able to controll as in the HIV early days 25 aids defining illnesses. and are look at all of those the
david - but is xmrv just a pass
judy - in geernaly rv don't just hang out but we expect to see that it will cause problems
???? negative studys we still don't know reported on the disease since 1984 they have depression the emperic definition have 38% depression we don't know but let's define the patient, but we have people who have been sick for 40 or more years, RKI didn't switzer and trade sample s with a lab that
stoy - enogh nobodys trying to get a negivtive results.
hj -
stoy -
coffin - we got to get this sort this out before we start druggs but we are not their mean time lay off the drugs
??? don't offten find rv most gibbons don't get ill
sniderman ny- passager virus?? since you can't give the kocks postulate how can the find pathogensis
john - hiv giving the arv showing the disease was an argument for showing causality but we had a lot more science under us befoer that happened and we don't have the at yet. Nowif we could quaintative assays then maybe yeat then maybe we could
???? hiv and hemophiliacs so you were closer
coffin - but until we get the right assessys
bell- progress hive thour the mistakes we lost people who were not able to side effect to tret people with the drugs to keep from making the same mistakes
???- we learned a lot from HIV epidemic and the hemophilia took the brunt of it, dr. bell? but I have to say that that NHIBL repository's helped to make linked to donor and recipiant and tap and try to identify xmrv epidemiology
??? don't take a heterogenoud groups gets assembling a group of patiens with cfs and well as controls and dfine and standard collection and establish and if you can quanitiy it then you could do a clinic trial but we have to define the patients. we need a step wise approach and do phase 1 and 2 and then longer term for clinica benifit
judy - hundreds xmrv positie people who are very sick and the commentary in those patient population and have not had a life for 25 years and more than the
???? i think you are on the right track but independy validated, and not the underliying sceptiums of people who are bed bound, and extended to diffrent groups
judy - independent groups validated and the patient exits, three positive and posters and followed using dersu assays. there are signiicant numbers with the virus from diffrent gourps
coffin - quaintative virus assay in a patient cohort and then maybe do a study to look at the arv could happen soon but the assasys that we have now but we need a quaintave assay that gives u a reproducable result. Then we could do something like tat with cross overs and monitor clinicly.
stoy - other issues
nation c inst - HPV animal model then you can make it certain, induce illness,
